• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: HALYARD - IRVINE ON-Q C-BLOC WITH DUAL SELECT-A-FLOW 600 ML X 1-7 ML/HR + 1-7 ML/HR; ELASTOMERIC - SAF

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

HALYARD - IRVINE ON-Q C-BLOC WITH DUAL SELECT-A-FLOW 600 ML X 1-7 ML/HR + 1-7 ML/HR; ELASTOMERIC - SAF Back to Search Results
Model Number CB6007
Medical Device Problem Code Adverse Event Without Identified Device or Use Problem (2993)
Health Effect - Clinical Codes Unspecified Infection (1930); No Code Available (3191)
Type of Reportable Event Serious Injury
Additional Manufacturer Narrative
(b)(4).The actual complaint product was not returned for evaluation.The device history record for the reported lot number, 0202520866, was reviewed and documented that the lot was manufactured according to the approved manufacturing procedures, specifications, and then released by quality assurance.All information reasonably known as of 03-aug-2017 has been included in this health authority report.Should additional information be obtained, a follow-up health authority report will be provided.The information provided by halyard health represents all of the known information at this time.Despite good faith efforts to obtain additional information, the complainant / reporter was unable or unwilling to provide any further patient, product, or procedural details to halyard health.Halyard health has no independent knowledge of the event reported but is relaying the information that was provided by the user facility where the incident occurred.This product incident is documented in the halyard health complaint database and identified as complaint (b)(4).Device not returned.
 
Event or Problem Description
Fill volume: 600 ml, flow rate: 7+7 ml/hr, procedure: total hysterectomy, cathplace: bilateral midline subfascial.It was reported that a patient was readmitted to the hospital for necrotizing fasciitis.The patient presented in the emergency room a week after her surgery.The patient was educated before her discharge on pulling the catheters at home.The patient complained of right flank pain and a distended belly.There was no redness at the catheter site.Additional information received on 19-jul-2017 stated that the patient had a total hysterectomy (b)(6) 2017.The patient complained of right flank pain and had a distended belly so she was treated with a gas medication first.It was not until (b)(6) 2017 that the patient was readmitted for an infection.Additional information was requested but not yet received.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
ON-Q C-BLOC WITH DUAL SELECT-A-FLOW 600 ML X 1-7 ML/HR + 1-7 ML/HR
Common Device Name
ELASTOMERIC - SAF
Manufacturer (Section D)
HALYARD - IRVINE
43 discovery
suite 100
irvine CA 92618
MDR Report Key6770480
Report Number2026095-2017-00146
Device Sequence Number19069389
Product Code MEB
UDI-Device Identifier30680651134777
UDI-Public30680651134777
Combination Product (Y/N)N
Initial Reporter StateNM
Initial Reporter CountryUS
PMA/510(K) Number
K063530
Number of Events Summarized1
Summary Report (Y/N)N
Reporter Type Manufacturer
Report Source health professional,user faci
Initial Reporter Occupation Physician
Type of Report Initial
Report Date (Section B) 07/17/2017
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Operator of Device Lay User/Patient
Device Expiration Date02/15/2019
Device Model NumberCB6007
Device Catalogue Number101347704
Device Lot Number0202520866
Was Device Available for Evaluation? No
Type of Report(Section G)Thirty-Day
Initial Date Received by Manufacturer 07/17/2017
Initial Report FDA Received Date08/07/2017
Patient Sequence Number1
Concomitant Medical Products
and Therapy/Usage Dates
0.2% ROPIVACAINE
Outcome Attributed to Adverse Event Required Intervention;
-
-